Clinical trials: Insulin Secretion
Healthy
A Study to Evaluate the Use of a Graded Infusion of Intravenous Glucose in the Assessment of Insulin Secretion Rates (MK-0000-078)
A two period pilot study to determine if a graded glucose infusion using a glucose (20% dextrose [D20]) intravenous infusion can be properly implemented and will be well tolerated in healthy subjects.
- Trial name
- NCT01021462
- Testing
- Comparator: graded infusion of intravenous glucose
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion
A 3-week, multi-center, open-label, randomized, active-control, parallel-group study to compare effects of Nateglinide and Acarbose on postprandial glucose fluctuation in Chinese drug-naive patients type 2 diabetes mellitus…
- Trial name
- NCT01030952
- Testing
- Nateglinide, Acarbose
- Where
- 3 sites in China
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Insulin Sensitivity
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
The primary objective of Study GZQG is to compare the effect of retatrutide and placebo on total clamp disposition index (cDI) after 28 weeks of treatment.
- Trial name
- NCT06982859
- Testing
- Retatrutide, Semaglutide
- Where
- Germany
- Volunteers
- 95 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
The purpose of this study is to assess changes from baseline in insulin sensitivity, hepatic fat content and beta cell function after approximately 24-25 weeks of treatment with canagliflozin compared to placebo in participants…
- Trial name
- NCT02009488
- Testing
- Canagliflozin, 100 mg, Canagliflozin, 300 mg
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes
A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose
A Study to Assess the Effect of CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose in Obese Male Subjects and Subjects with T2DM.
- Trial name
- NCT04973111
- Testing
- CT-868 as SC Injection, Active Comparator as SC Injection
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Carmot Therapeutics, Inc.
Diabetes Mellitus Type 2
A Study of Taspoglutide in Type 2 Diabetic Patients
This crossover study will assess the effect of 2 doses of Taspoglutide on first- and second-phase insulin secretion in patients with type 2 diabetes.
- Trial name
- NCT00811460
- Testing
- taspoglutide
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus
Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying
Impact of combined Lantus (insulin glargine) and Lyxumia(lixisenatide) on insulin secretion and gastric emptying
- Trial name
- NCT01910194
- Testing
- Luyxumia versus Lantus
- Where
- 2 sites in Germany
- Volunteers
- 39 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Type 2 Diabetes Mellitus
Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes
The purpose of this study is to evaluate the effects of dapagliflozin on insulin sensitivity
- Trial name
- NCT00831779
- Testing
- Dapagliflozin
- Where
- 3 sites in United States
- Volunteers
- 116 people
- Sponsor
- AstraZeneca
Growth Hormone Deficiency
Comparative Validation of the Growth Hormone Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone Deficiency
The aim of the study is to determine the specificity and sensitivity of the combined growth hormone releasing hormone (GHRH) + Arginine test in healthy volunteers, subjects with highly probable adult growth hormone deficiency…
- Trial name
- NCT01060488
- Testing
- GHRH+Arg, GHRH+Arg, ITT, ITT, ITT, GHRH+Arg.
- Where
- France
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Merck KGaA, Darmstadt, Germany
Type 2 Diabetes Mellitus
A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)
This study will evaluate the effect of a single dose of sitagliptin on glucose dependent insulin secretion using a meal tolerance test (MTT) during a hyperglycemic clamp (HCG) procedure.
- Trial name
- NCT00888238
- Testing
- sitagliptin
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Study to Evaluate the Effect of Vildagliptin on the Maximum Insulin Secretion in Patients With Type 2 Diabetes
Type 2 diabetes results when the body does not produce enough insulin to regulate blood sugar. This study is designed to measure the effect of vildagliptin on the maximum insulin secretion by the pancreas.
- Trial name
- NCT00351585
- Testing
- Vildagliptin
- Volunteers
- 39 people
- Sponsor
- Novartis
Type 1 Diabetes Mellitus
Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)
This is a randomized, parallel group, double-blind Phase 2 study with a blinded extension evaluating the safety and efficacy of 3 dose levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on…
- Trial name
- FABULINUS (NCT06111586)
- Testing
- Frexalimab, Insulin
- Where
- 79 sites in United States, Austria and 14 more
- Volunteers
- 197 people
- Sponsor
- Sanofi
The Methodology Assessment of Glucose Dependent Insulin Secretion
A Study to Compare Methodologies for Assessing Glucose-Dependent Insulin Secretion (0000-104)(COMPLETED)
This study will compare graded glucose infusion (GGI) to the hyperglycemic clamp (HGC) for assessment of glucose-dependent insulin secretion (GDIS) using exenatide as a probe.
- Trial name
- NCT00782418
- Testing
- Comparator: exenatide
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to assess the effect of NNC 90-1170 (liraglutide) on pulsatile insulin secretion and insulin secretion after a standard meal in subjects with type 2 diabetes.
- Trial name
- NCT01507311
- Testing
- liraglutide
- Where
- Denmark
- Volunteers
- 11 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Study That Will Evaluate Ketogenesis and Glucose-Dependent Insulin Secretion Methodologies in Healthy Male Subjects (MK-0000-159)(COMPLETED)
This study will test the hypotheses that a single dose of oxyntomodulin (OXM) will be neutral or better than placebo in lowering ambient glucose levels during a graded glucose infusion (GGI) and that a single dose of OXM will…
- Trial name
- NCT01055340
- Testing
- Oxyntomodulin (OXM), Comparator: Oxyntomodulin (OXM)
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Obesity
Evaluation of the Efficacy of the Composite WM Formula in Promoting GLP-1 Secretion
The goal of this clinical trial is to evaluate the physiological effects of a WM Formula on glucagon-like peptide-1 (GLP-1) secretion and glycemic regulation in adults with elevated body fat percentage.
- Trial name
- NCT07097987
- Testing
- WM formula Group, Control group
- Where
- Taiwan
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- TCI Co., Ltd.
Healthy
A Study to Assess the Effects of Exenatide on Insulin Secretion Rates Using a Graded Infusion of Intravenous Glucose (0000-099)(COMPLETED)
A four-period study to evaluate if the grade glucose infusion procedure will be able to detect an increase in beta-cell glucose sensitivity from exenatide compared to no treatment in healthy subjects.
- Trial name
- NCT01021527
- Testing
- Comparator: Treatment A, Comparator: Treatment B, Comparator: Treatment C
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose
The purpose of this study is to measure the effect of LY2189265 to increase insulin levels in response to glucose intake.
- Trial name
- NCT01300260
- Testing
- LY2189265, Insulin, Glucose
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Non-Alcoholic Fatty Liver Disease
Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD
This clinical trial aims to investigate the effects of TOTUM-448, a mix of 5 plant extracts and choline, consumed at the daily regimen of two times per day, on liver fat content, cardiometabolic risk factors and gut microbiota…
- Trial name
- CARDIO-LIVER (NCT06704321)
- Testing
- TOTUM-448
- Where
- Canada
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Valbiotis